Hunan Nucien Pharmaceutical Co (SHSE:688189) Research & Development: ¥29.2 Mil (TTM As of Mar. 2026)


SHSE:688189 Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
52 GF Score
Price ¥5.98
GF Value ¥2.38
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Hunan Nucien Pharmaceutical Co Research & Development?

Hunan Nucien Pharmaceutical Co SHSE:688189 -1.32% 52 Research & Development is ¥29.2 Mil as of Mar. 2026. GuruFocus rates SHSE:688189 with a GF Score™ of 52/100 and a GF Value™ of ¥2.38 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hunan Nucien Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was ¥4.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥29.2 Mil.

Hunan Nucien Pharmaceutical Co  (SHSE:688189) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hunan Nucien Pharmaceutical Co Research & Development Related Terms

Hunan Nucien Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Hunan Nucien Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Nucien Pharmaceutical Co Research & Development Chart

Hunan Nucien Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.03 58.16 74.86 48.81 35.36

Hunan Nucien Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.42 7.13 9.75 8.06 4.26
SHSE:688189
52GF Score
Hunan Nucien Pharmaceutical Co Ltd SHSE:688189
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hunan Nucien Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥29.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥29.2 Mil mean?
Hunan Nucien Pharmaceutical Co (SHSE:688189) has a Research & Development of ¥29.2 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hunan Nucien Pharmaceutical Co and its competitors.
Is Hunan Nucien Pharmaceutical Co's Research & Development too high?
Hunan Nucien Pharmaceutical Co's current Research & Development is ¥29.2 Mil. Overall, Hunan Nucien Pharmaceutical Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Nucien Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Hunan Nucien Pharmaceutical Co's Research & Development of ¥29.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hunan Nucien Pharmaceutical Co and its competitors. Hunan Nucien Pharmaceutical Co's current Research & Development is ¥29.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Nucien Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co (SHSE:688189) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥2.38, compared to a current price of ¥5.98 — trading 151.3% above its estimated fair value. The current Research & Development is ¥29.2 Mil. Hunan Nucien Pharmaceutical Co's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hunan Nucien Pharmaceutical Co (SHSE:688189), the current Research & Development is ¥29.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hunan Nucien Pharmaceutical Co (SHSE:688189) Overvalued in 2026?

Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥5.98 is trading 151.3% above its estimated GF Value™ of ¥2.38. GuruFocus considers Hunan Nucien Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:688189:

  • Research & Development: ¥29.2 Mil
  • GF Value™: ¥2.38 vs. price of ¥5.98 (151.3% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hunan Nucien Pharmaceutical Co Business Description

Address No. 1 Kangli Road, Liuyang Economic and Technological Development Zone, Hunan Province, Changsha, CHN, 510100
Hunan Nucien Pharmaceutical Co Ltd is a pharmaceutical company integrating drug research and development, production and sales. The company focuses on anti-infection, cardio-cerebral vascular, anti-tumor and other pharmaceutical fields. The company's business scope includes the manufacturing and sales of chemical pharmaceutical preparations, chemical pharmaceutical raw materials, biological drugs, chemical reagents, and auxiliaries.
52GF Score

Get the complete analysis for SHSE:688189

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.98
Price
¥2.38
GF Value